Veracyte Q2 revenues rise 32%

By staff writers

August 3, 2022 -- Veracyte on Tuesday reported second quarter (end-June 30) total revenues of $72.9 million, an increase of 32% compared to $55.1 million in Q2 2021.

In the most recent quarter, Veracyte posted testing revenues of $59.7 million, an increase of 18% compared to $50.8 million in Q2 2021, driven primarily by the strong performance of its urology tests.

Product revenue in the second quarter of 2022 was $3.1 million, an increase of 16% compared to $2.7 million in the same period of 2021.

Its Q2 biopharmaceutical and other revenue was $10 million, compared to $1.6 million in the prior-year period, an increase driven primarily by the acquisition of HalioDx.

The company's Q2 net loss widened to $9.5 million from $9.0 million in Q2 2021.

Veracyte announces study results for thyroid cancer classifier
Veracyte announced Wednesday that its thyroid cancer genomic test showed high sensitivity and specificity in detecting medullary thyroid cancer (MTC)...
Veracyte genomic test classifies lung cancer risk in study
Lung cancer patients with inconclusive bronchoscopy results have just received encouraging news that their tests can now be more accurately classified...
Veracyte announces evidence supporting thyroid genomic test
Veracyte said that a new meta-analysis provides evidence that its Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in...
Veracyte touts gene expression study data at ESMO meeting
Gene expression profile (GEP) testing helps guide treatment decisions for women with early-stage breast cancer, according to a presentation from Veracyte...
Veracyte to highlight new Decipher data at ASCO meeting
Veracyte plans to highlight data from six poster abstracts regarding its Decipher urologic cancer tests at the upcoming American Society of Clinical Oncology...

Copyright © 2022

Last Updated lo 8/4/2022 4:22:15 AM